Administrative Core

行政核心

• 批准号: 8042570
• 负责人: DAVID H WALKER
• 金额: $ 93.69万
• 依托单位: UNIVERSITY OF TEXAS MED BR GALVESTON
• 依托单位国家: 美国
• 财政年份: 2010
• 资助国家: 美国
• 起止时间: 2010-03-01 至 2014-02-28
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8042570
• 关键词: Academia; Acellular Vaccines; Adjuvant; Alphavirus; Animal Model; Animal Welfare; Animals; Anthrax disease; Antibodies; Antigens; Antiviral Agents; Applied Research; Area; Arenavirus; Arkansas; Attenuated; Attenuated Vaccines; Bacillus anthracis spore; Bacteria; Basic Science; Binding Sites; Bioinformatics; Biological Assay; Biotechnology; Brucella Vaccine; Brucella melitensis; Burkholderia mallei; Capsid; Caring; Categories; Cells; Chemicals; Chikungunya virus; Chimera organism; Chromatography; Clinic; Clinical; Clinical Pathology; Cloning; Code; Collaborations; Collection; Communicable Diseases; Communities; Complement; Computational Biology; Consult; Core Facility; Coupled; Coxiella burnetii; Cryptosporidium; Culicidae; Cyclic Peptides; DNA Resequencing; Data; Data Analyses; Data Set; Databases; Dengue; Detection; Developing Countries; Development; Diagnosis; Diagnostic; Diagnostic tests; Diarrhea; Disease; Disulfides; Drug Industry; Emergency Situation; Emerging Communicable Diseases; Employment; Encephalitis Viruses; Endemic Flea-Borne Typhus; Epidemic; Epitopes; Equilibrium; Equine Encephalomyelitis; Event; Experimental Designs; Family; Filovirus; Flavivirus; Francisella tularensis; Frankfurt-Marburg Syndrome Virus; Funding; Future; Genes; Genetic screening method; Genomics; Geographic Locations; Germination; Glanders; Goals; Grant; Human; Human Resources; Immune Targeting; Immunity; In Vitro; Individual; Infection; Infectious Agent; Infectious Diseases Research; Institution; Intellectual Property; Interdisciplinary Study; International Aspects; Internet; Intestines; Investigation; Japanese Encephalitis; Junin virus; Knowledge; Laboratories; Lateral; Laws; Lead; Leadership; Leg; Legal; Legal patent; Life; Ligands; Lipid A; Lipopolysaccharides; Literature; Louisiana; Measurement; Medical; Melioidosis; Membrane; Membrane Proteins; Microarray Analysis; Microencapsulations; Microfluidics; Mission; Modeling; Molecular; Molecular Conformation; Mutation; Names; National Institute of Allergy and Infectious Disease; Natural History; Nature; New Mexico; Nipah Virus; Norovirus; Nucleic Acids; O Antigens; Oklahoma; Oligonucleotide Probes; Open Reading Frames; Organism; Orthobunyavirus; Parasites; Participant; Pathogenesis; Pathway interactions; Peptides; Performance; Pharmaceutical Preparations; Phase; Phase I Clinical Trials; Policy Analysis; Primates; Prions; Process; Proteins; Proteome; Proteomics; Protozoa; Publications; Q Fever; Qualifying; RNA Viruses; Reagent; Recombinant Proteins; Regulation; Research; Research Activity; Research Infrastructure; Research Personnel; Research Project Grants; Research Training; Resources; Rickettsia; Rift Valley Fever; Rift Valley fever virus; Rodent; Role; SARS coronavirus; Safety; Salmonella; Sampling; Scheme; Science; Scientist; Services; Site; Slide; Spottings; Strategic Planning; Structure; Subunit Vaccines; Sum; T-Lymphocyte; Tadpoles; Techniques; Technology; Testing; Texas; Text; Therapeutic; Therapeutic Agents; Time; Toxin; Training; Translational Research; Translations; Tularemia; Uncertainty; Universities; Vaccinated; Vaccines; Venezuelan Equine Encephalitis Virus; Venezuelan Equine Encephalomyelitis; Viral; Virulence; Virulence Factors; Virus; Virus Diseases; Virus-like particle; Walkers; Work; Yellow Fever; aptamer; bacterial genetics; base; biodefense; biothreat; capsule; commercialization; computer code; cost; crosslink; design; env Gene Products; federal policy; high throughput screening; human subject; immunogenic; in vivo; inhibitor/antagonist; innovation; instrumentation; man; member; molecular recognition; nanoparticle; neglect; new technology; nonhuman primate; novel; novel strategies; novel therapeutics; optical sensor; particle; pathogen; point of care; point-of-care diagnostics; programs; receptor; research and development; research study; response; stem; success; sugar; therapeutic vaccine; tool; vaccine development; vaccine evaluation; virus genetics

The Western Regional Center of Excellence for Biodefense and Emerging Infectious Diseases Research (WRCE) is located in DHHS Region VI, including Texas, New Mexico, Oklahoma, Arkansas, and Louisiana. Dr. David H. Walker is the PI and director for the WRCE. The University of Texas Medical Branch at Galveston (UTMB) is the lead institution. Academic institutions within the WRCE possess remarkable depth and breadth of scientific expertise related to Category A, B, and C priority pathogens and emerging and re-emerging infectious disease agents. From the very beginning, the WRCE leadership has strived to access this expertise and to make the WRCE a genuine cross-institutional Center involving all member states, not just in name or by concentrating projects at a few universities. The fact that over 100 project leaders at 34 different institutions have received funding from the WRCE is a testament to the plural nature of the WRCE program. The sense of collaboration and spirit of cooperation among investigators from traditionally competing institutions was previously unimaginable prior to the establishment of the WRCE in 2003 under Dr. Walker's guidance and strong leadership. The activities of the WRCE are firmly centered on supporting NIAID's Biodefense Research Agenda, and this application reaffirms our commitment to this strategy. The WRCE program is a success, as evaluated by a number of parameters that consider the whole Center as contributing more than the sum of its individual member institutions and investigators. In the assessment of the national RCE Program, several individual Center measurements were provided. They revealed that the WRCE ranked first in the number of organisms studied, total number of projects, number of Pis, additional non- RCE funding stemming from WRCE research, and number of patent applications as compared to the other individual Centers [1]. Our publication rate is also the one of the highest of the Centers. Since the WRCE was originally funded in September 2003, excellent progress has been made toward producing promising leads for biodefense countermeasures. WRCE translational research resulted in a wealth of significant basic biologic research as well, and the two are not mutually exclusive. Publications from WRCE researchers have resulted in new knowledge about the role of capsule in dissemination of inhalational anthrax, anthrax spore germination, rickettsial genes involved in phagosomal escape, the role of nonstructural genes in the replication of Rift Valley fever virus, the genetics of Nipah virus, and Venezuelan equine encephalitis virus host cell entry mechanisms, to name but a few. Additionally, the well characterized animal models developed by the WRCE Small Animal Core, Nonhuman Primate Core, and select project leaders all contributed knowledge about the natural history and pathogenesis of infections, and these investigations are an essential component for supporting applied research. The original WRCE application in 2003 had a very broad thematic structure in the strategic plan. The focus of the WRCE leadership was to fund the very best science and to take full advantage of the diversity of infectious disease and microbiologic expertise in our region. To date, the WRCE has funded 72 research projects and ten cores, including two trans-RCE cores that resided in our region. This work involved 30 different agents, including nine bacteria, 18 viruses, one protozoan, and two toxins. Given the yield in WRCE patents and publications, the institutions and investigators receiving funding, and projects advancing toward tangible products, this strategy served us very well during the first grant cycle. As the WRCE program matured, four themes emerged that logically encompassed the most productive projects that were likely to lead to biodefense countermeasures. The four themes are as follows: 1. Development of Therapeutic Agents for RNA Viruses 2. Platforms for Multiplexed Diagnostics for Category A-C Agents and Emerging Agents 3. Vaccine Development for Arboviral and Emerging Viral Diseases 4. Vaccine Development for Diseases Caused by Intracellular Bacteria These themes will no doubt serve to help us converge and synergize as we embark on the next leg of our research journey within the WRCE

西部地区生物防御和新发传染病研究卓越中心 (WRCE)位于国土安全部第六区，包括德克萨斯州、新墨西哥州、俄克拉何马州、阿肯色州和路易斯安那州。Dr。 大卫·H·沃克是WRCE的私家侦探兼主任。德克萨斯大学加尔维斯顿分校 (UTMB)是牵头机构。WRCE内的学术机构具有非凡的深度和广度 与A、B和C类优先病原体以及新出现和重新出现的病原体有关的科学专门知识 传染病病原体。从一开始，WRCE领导层就努力获得这些专业知识 并使WRCE成为一个真正的跨机构中心，涉及所有成员国，而不仅仅是名义上或通过 将项目集中在几所大学。34个不同机构的100多名项目负责人 都得到了WRCE的资助，这证明了WRCE计划的多元性。一种感觉 来自传统上相互竞争的机构的调查人员之间的协作和合作精神 在2003年沃克博士的指导下成立WRCE之前，这在以前是不可想象的 强有力的领导力。WRCE的活动坚定地以支持NIAID的生物防御研究为中心 议程，这项申请重申了我们对这一战略的承诺。 WRCE计划是成功的，通过考虑整个中心的许多参数进行评估 其贡献超过其个别成员机构和调查人员的总和。在评估中 在国家RCE计划中，提供了几个独立中心的测量结果。他们透露， WRCE在研究的生物体数量、项目总数、PI数量、额外的非 来自WRCE研究的RCE资金，以及与其他专利申请数量的比较 个人中心[1]。我们的发表率也是中心中最高的之一。因为WRCE是 最初于2003年9月资助，在为 生物防御对策。WRCE的翻译研究产生了丰富的重要基础生物学 研究也是如此，两者并不是相互排斥的。来自WRCE研究人员的出版物导致了 关于胶囊在吸入性炭疽、炭疽孢子传播中作用的新认识 发芽、立克次体基因参与吞噬体逃逸、非结构基因在复制中的作用 裂谷热病毒、尼帕病毒的遗传学和委内瑞拉马脑炎病毒宿主细胞的进入 机制，仅举几个例子。此外，WRCE开发的具有良好特性的动物模型 小动物核心、非人类灵长类核心和精选的项目负责人都贡献了关于 感染的自然病史和发病机制，这些调查是 支持应用研究。 2003年最初的WRCE申请在战略计划中有一个非常广泛的主题结构。这个 WRCE领导层的重点是资助最好的科学并充分利用多样性 传染病和微生物学专业知识在我们地区的应用。到目前为止，WRCE已经资助了72项研究 项目和十个核心，包括驻留在我们区域的两个跨RCE核心。这项工作涉及30人 不同的病原体，包括9种细菌、18种病毒、1种原生动物和2种毒素。鉴于WRCE的收益率 专利和出版物，接受资助的机构和调查人员，以及向 对于有形产品，这一战略在第一个赠款周期中发挥了很好的作用。作为WRCE计划 成熟后，出现了四个主题，它们逻辑上围绕着最具生产力的项目，可能会 导致生物防御对策。这四个主题如下： 1.RNA病毒治疗药物的研究进展 2.A-C类代理和新兴代理的多路诊断平台 3.虫媒病毒和新出现的病毒性疾病的疫苗开发 4.细胞内细菌引起的疾病疫苗的研制 这些主题无疑将有助于我们在开始下一阶段的 WRCE中的研究之旅